DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ibandronate (Ibandronate Sodium) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Adverse reactions that appear in other sections of the labeling include:

  • Hypocalcemia and Mineral Metabolism [see Warnings and Precautions ]
  • Anaphylactic Reaction [see Warnings and Precautions]
  • Renal Impairment [see Warnings and Precautions ]
  • Tissue Damage Related to Inappropriate Drug Administration [see Warnings and Precautions]
  • Osteonecrosis of the Jaw [see Warnings and Precautions ]
  • Musculoskeletal Pain [see Warnings and Precautions]
  • Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions ]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Quarterly Intravenous Injection

In a 1-year, double-blind, multicenter study comparing ibandronate sodium injection administered intravenously as 3 mg (ibandronate) every 3 months to ibandronate 2.5 mg daily oral tablet in women with postmenopausal osteoporosis, the overall safety and tolerability profiles of the two dosing regimens were similar. The incidence of serious adverse reactions was 8.0% in the ibandronate 2.5 mg daily group and 7.5% in the ibandronate sodium injection 3 mg (ibandronate) once every 3 months group. The percentage of patients who withdrew from treatment due to adverse reactions was approximately 6.7% in the ibandronate 2.5 mg daily group and 8.5% in the ibandronate sodium injection 3 mg (ibandronate) every 3 months group. Table 1 lists the adverse reactions reported in greater than 2% of patients.

Table 1 Adverse Reactions With an Incidence of at Least 2% in Patients Treated with Ibandronate Sodium Injection (3 mg [ibandronate] once every 3 months) or Ibandronate Daily Oral Tablet (2.5 mg)

* Combination of abdominal pain and abdominal pain upper

† Combination of influenza-like illness and acute phase reaction

‡ Combination of rash, rash pruritic, rash macular, dermatitis, dermatitis allergic, exanthema, erythema, rash papular, rash generalized, dermatitis medicamentosa, rash erythematous



Body System/Adverse Reaction

Ibandronate
2.5 mg Daily (Oral)
% (n=465)
Ibandronate Sodium Injection
3 mg (ibandronate) every 3 months (Intravenous)
%
(n=469)
Infections and Infestations
     Influenza 8 5
     Nasopharyngitis 6 3
     Cystitis 3 2
     Gastroenteritis 3 2
     Urinary Tract Infection 3 3
     Bronchitis 3 2
     Upper Respiratory Tract Infection 3 1
Gastrointestinal Disorders
     Abdominal Pain* 6 5
     Dyspepsia 4 4
     Nausea 4 2
     Constipation 4 3
     Diarrhea 2 3
     Gastritis 2 2
Musculoskeletal and Connective
Tissue Disorders
     Arthralgia 9 10
     Back Pain 8 7
     Localized Osteoarthritis 2 2
     Pain in Extremity 2 3
     Myalgia 1 3
Nervous System Disorders
     Dizziness 3 2
     Headache 3 4
Psychiatric Disorders
     Insomnia 3 1
     Depression 2 1
General Disorders and
Administration Site Conditions
     Influenza-like Illness† 1 5
     Fatigue 1 3
Skin and Subcutaneous Tissue
Disorders
     Rash‡ 3 2

Acute Phase Reaction-like Events

Symptoms consistent with acute phase reaction (APR) have been reported with intravenous bisphosphonate use. The overall incidence of patients with APR-like events was higher in the intravenous treatment group (4% in the ibandronate 2.5 mg daily oral tablet group vs. 10% in the ibandronate sodium injection 3 mg (ibandronate) once every 3 months group). These incidence rates are based upon reporting of any of 33 potential APR-like symptoms within 3 days of an intravenous dose and lasting 7 days or less. In most cases, no specific treatment was required and the symptoms subsided within 24 to 48 hours.

Injection Site Reactions

Local reactions at the injection site, such as redness or swelling, were observed at a higher incidence in patients treated with ibandronate sodium injection 3 mg (ibandronate) every 3 months (1.7%; 8/469) than in patients treated with placebo injections (0.2%; 1/465). In most cases, the reaction was of mild to moderate severity.

Daily Oral Tablet

The safety of ibandronate 2.5 mg once daily in the treatment and prevention of postmenopausal osteoporosis was assessed in 3577 patients aged 41 – 82 years. The duration of the trials was 2 to 3 years, with 1134 patients exposed to placebo and 1140 exposed to ibandronate 2.5 mg. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs, proton pump inhibitors and H2 antagonists were included in these clinical trials. All patients received 500 mg calcium plus 400 international units vitamin D supplementation daily.

The incidence of all-cause mortality was 1% in the placebo group and 1.2% in the ibandronate 2.5 mg daily group. The incidence of serious adverse reactions was 20% in the placebo group and 23% in the ibandronate 2.5 mg daily oral tablet group. The percentage of patients who withdrew from treatment due to adverse reactions was approximately 17% in both the placebo group and the ibandronate 2.5 mg daily oral tablet group. Table 2 lists adverse reactions from the Treatment and Prevention Studies reported in greater than or equal to 2% of patients and in more patients treated with ibandronate 2.5 mg daily oral tablet than patients treated with placebo.

Table 2 Adverse Reactions Occurring at an Incidence greater than or equal to 2% and in More Patients Treated with Ibandronate 2.5 mg Daily Oral Tablet than in Patients Treated with Placebo in the Osteoporosis Treatment and Prevention Studies
Body System Placebo
%
(n=1134)
Ibandronate 2.5 mg daily
%
(n=1140)
Body as a Whole
     Back Pain 12 14
     Pain in Extremity 6 8
     Asthenia 2 4
     Allergic Reaction 2 3
Digestive System
     Dyspepsia 10 12
     Diarrhea 5 7
     Tooth Disorder 2 4
     Vomiting 2 3
     Gastritis 2 2
Musculoskeletal System
     Myalgia 5 6
     Joint Disorder 3 4
     Arthritis 3 3
Nervous System
     Headache 6 7
     Dizziness 3 4
     Vertigo 3 3
Respiratory System
     Upper Respiratory 33 34
     Infection
     Bronchitis 7 10
     Pneumonia 4 6
     Pharyngitis 2 3
Urogenital System
     Urinary Tract Infection 4 6

Gastrointestinal Adverse Reactions

The incidence of selected gastrointestinal adverse reactions in the placebo and ibandronate 2.5 mg daily groups were: dyspepsia (10% vs. 12%), diarrhea (5% vs. 7%), and abdominal pain (5% vs. 6%).

Musculoskeletal Adverse Reactions

The incidence of selected musculoskeletal adverse reactions in the placebo and ibandronate 2.5 mg daily groups were: back pain (12% vs. 14%), arthralgia (14% vs. 14%) and myalgia (5% vs. 6%).

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of ibandronate sodium injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity: Allergic reactions including anaphylaxis with fatalities, angioedema, asthma exacerbation, bronchospasm, and rash [see Contraindications (4), Warnings and Precautions ].

Hypocalcemia: Hypocalcemia [see Warnings and Precautions].

Renal Toxicity: Acute renal failure [see Warnings and Precautions ].

Osteonecrosis of the Jaw: Osteonecrosis of the jaw [see Warnings and Precautions].

Musculoskeletal Pain: Bone, joint, or muscle pain (musculoskeletal pain), described as severe or incapacitating [see Warnings and Precautions ].

Atypical Femoral Shaft Fracture: Atypical, low-energy, or low-trauma fractures of the femoral shaft [see Warnings and Precautions].

Eye Inflammation: Iritis and uveitis. In some cases with other bisphosphonates, these events did not resolve until the bisphosphonate was discontinued.

Drug label data at the top of this Page last updated: 2014-04-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017